WO2023231388A1 - 一种用于治疗男性前列腺炎的药物及其应用 - Google Patents
一种用于治疗男性前列腺炎的药物及其应用 Download PDFInfo
- Publication number
- WO2023231388A1 WO2023231388A1 PCT/CN2022/141217 CN2022141217W WO2023231388A1 WO 2023231388 A1 WO2023231388 A1 WO 2023231388A1 CN 2022141217 W CN2022141217 W CN 2022141217W WO 2023231388 A1 WO2023231388 A1 WO 2023231388A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- parts
- levofloxacin
- medicine
- medical
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims abstract description 34
- 201000007094 prostatitis Diseases 0.000 title claims abstract description 23
- 239000000203 mixture Substances 0.000 claims abstract description 60
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 13
- GSDSWSVVBLHKDQ-JTQLQIEISA-N Levofloxacin Chemical compound C([C@@H](N1C2=C(C(C(C(O)=O)=C1)=O)C=C1F)C)OC2=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-JTQLQIEISA-N 0.000 claims abstract description 13
- 239000012153 distilled water Substances 0.000 claims abstract description 13
- 239000008103 glucose Substances 0.000 claims abstract description 13
- 229960003376 levofloxacin Drugs 0.000 claims abstract description 13
- 229940018978 levofloxacin injection Drugs 0.000 claims abstract description 13
- 229940025300 lidocaine injection Drugs 0.000 claims abstract description 13
- 239000000843 powder Substances 0.000 claims abstract description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 208000011580 syndromic disease Diseases 0.000 claims abstract description 9
- 230000010412 perfusion Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims 3
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 3
- 206010059866 Drug resistance Diseases 0.000 description 2
- 206010046555 Urinary retention Diseases 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Definitions
- the invention relates to the technical field of drugs for male diseases, and specifically refers to a drug for treating male prostatitis and its application.
- Prostatitis and prostatitis syndrome generally exist in men after the age of 40, and this syndrome cannot be accurately diagnosed through B-ultrasound, and it is also difficult to detect its existence during electrosurgical surgery. There is no method that can effectively solve the above problems in the prior art, thus causing a certain amount of pain to the patient.
- the present invention proposes a medicine capable of curing prostatitis syndrome.
- a medicine for treating male prostatitis including composition A and composition B, wherein the composition A includes 2-8 parts of medical distilled water and 2-8 parts of lidocaine injection, and the composition B It includes 80-120 parts of levofloxacin injection and 8-12 parts of medical glucose powder, and the concentration of levofloxacin is 0.2%.
- composition A is used for one urethral perfusion
- composition B is used for the second urethral perfusion
- composition A includes composition A and composition B, wherein the composition A includes 2 parts of medical distilled water and 2 parts of lidocaine injection, and the composition B includes 80 parts of levofloxacin injection and 8 parts of medical glucose powder. , the concentration of levofloxacin is 0.2%.
- composition A includes composition A and composition B, wherein the composition A includes 8 parts of medical distilled water and 8 parts of lidocaine injection, and the composition B includes 120 parts of levofloxacin injection and 12 parts of medical glucose powder. , the concentration of levofloxacin is 0.2%.
- composition A includes composition A and composition B, wherein the composition A includes 5 parts of medical distilled water and 5 parts of lidocaine injection, and the composition B includes 100 parts of levofloxacin injection and 10 parts of medical glucose powder. , the concentration of levofloxacin is 0.2%.
- composition A By proposing a substance between composition A and composition B, it not only achieves the function of convenient clinical use, but also can achieve the effect of improving the cure rate and reducing the recurrence rate. It has strong practicability and functionality, and is clinically effective. Practical and safe.
- a medicine for treating male prostatitis characterized by comprising composition A and composition B, wherein said composition A includes 2-8 parts of medical distilled water and 2-8 parts of lidocaine injection, so
- the composition B includes 80-120 parts of levofloxacin injection and 8-12 parts of medical glucose powder, and the concentration of levofloxacin is 0.2%.
- the above medications are used to treat prostatitis syndrome in men.
- the medicine of the present invention When the medicine of the present invention combines prostatitis syndrome with prostatic hyperplasia, urinary retention occurs, and if the indication for surgical treatment has not yet appeared (residual urine is less than 60ML), the present invention adds prostate massage, prostate microwave, and effective antibiotics. A comprehensive treatment plan, implemented for 2 to 3 weeks, will achieve a satisfactory treatment effect for the patient.
- a medicine for treating male prostatitis including composition A and composition B, wherein the composition A includes 2 parts of medical distilled water and 2 parts of lidocaine injection, and the composition B includes levofloxacin injection 80 parts and 8 parts of medical glucose powder, and the concentration of levofloxacin is 0.2%.
- composition A is used for one urethral perfusion every day, and composition B is used for the second urethral perfusion. If it is not filled into the urethra, do it again until it is filled into the urethra.
- a medicine for treating male prostatitis including composition A and composition B, wherein the composition A includes 8 parts of medical distilled water and 8 parts of lidocaine injection, and the composition B includes levofloxacin injection 120 parts and 12 parts of medical glucose powder, and the concentration of levofloxacin is 0.2%.
- a medicine for treating male prostatitis including composition A and composition B, wherein the composition A includes 5 parts of medical distilled water and 5 parts of lidocaine injection, and the composition B includes levofloxacin injection 100 parts and 10 parts of medical glucose powder, and the concentration of levofloxacin is 0.2%.
- the patients are divided into an experimental group, a comparison group and a blank group, with 10 people in each group.
- the experimental group takes the medicine provided by the present invention
- the comparison group takes the medicine of the prior art
- the blank group does not take any medicine and undergoes a three-month study. Observe and record experiments.
- the effect of curing prostatitis patients can be achieved, and the recurrence rate is low and the effect is obvious, thereby greatly reducing the treatment cost, being highly functional, and solving the psychological problem of drug resistance of patients taking medicine for a long time.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明提供一种用于治疗男性前列腺炎的药物，包括组合物A和组合物B，其中所述组合物A包括2-8份医用蒸馏水、2-8份利多卡因注射液，所述组合物B包括左氧氟沙星注射液80-120份、医用葡萄糖粉 8-12份，所述左氧氟沙星的浓度为0.2%。该药物可用于治疗男性前列腺炎综合症。
Description
本发明涉及男性疾病药物技术领域，具体是指一种用于治疗男性前列腺炎的药物及其应用。
前列腺炎与前列腺炎综合症一般存在于40岁以后的男性人群中，且这种综合症状通过B超无法准确诊断出来，且在电刀手术过程中也很难发现其存在。现有技术中并没有能够有效解决上述问题的方法，从而给患者造成了一定的痛苦。
因此，一种能够针对上述问题进行治疗的药物有待提出。
发明内容
针对以上问题，本发明提出了一种能够实现治愈前列腺炎综合症的药物的。
本发明提供的技术方案为：
一种用于治疗男性前列腺炎的药物，包括组合物A和组合物B，其中，所述组合物A包括2-8份医用蒸馏水、2-8份利多卡因注射液，所述组合物B包括左氧氟沙星注射液80-120份、医用葡萄糖粉8-12份，所述左氧氟沙星的浓度为0.2％。
优选地，在使用过程中，分别利用组合物A做一次尿道灌注，以及利用组合物B进行第二次尿道灌注。
优选地，包括组合物A和组合物B，其中，所述组合物A包括2份医用蒸馏水、2份利多卡因注射液，所述组合物B包括左氧氟沙星注射液80份、医用葡萄糖粉8份，所述左氧氟沙星的浓度为0.2％。
优选地，包括组合物A和组合物B，其中，所述组合物A包括8份医用蒸馏水、8份利多卡因注射液，所述组合物B包括左氧氟沙星注射液120份、医用葡萄糖粉12份，所述左氧氟沙星的浓度为0.2％。
优选地，包括组合物A和组合物B，其中，所述组合物A包括5份医用蒸馏水、5份利多卡因注射液，所述组合物B包括左氧氟沙星注射液100份、医用葡萄糖粉10份，所述左氧氟沙星的浓度为0.2％。
本发明还提供了一种技术方案：
一种如上述所述的药物的应用，所述药物用于治疗男性前列腺炎综合症。
本发明与现有技术相比的优点在于：
通过提出一种带有组合物A和组合物B之间的物质，不但实现了方便临床使用的功能，而且能够达到提高治愈率以及降低复发率的作用，实用性和功能性强，且药物临床实用安全。
下面结合实施例对本发明做进一步的详细说明。
一种用于治疗男性前列腺炎的药物，其特征在于，包括组合物A和组合物B，其中，所述组合物A包括2-8份医用蒸馏水、2-8份利多卡因注射液，所述组合物B包括左氧氟沙星注射液80-120份、医用葡萄糖粉8-12份，所述左氧氟沙星的浓度为0.2％。
本发明还提供了一种技术方案：
将上述药物用于治疗男性前列腺炎综合症。
本发明药物在前列腺炎综合症合并前列腺增生的时候，发生的尿潴留，如果手术治疗的指征尚未出现，(残余尿不到60ML)，本发明加前列腺按摩加前列腺微波加有效抗生素的这样一个综合治疗方案，实施2一3周，将达成患者满意的治疗效果。
下面通过具体的实施例来对本发明进行具体的说明。
实施例一
一种用于治疗男性前列腺炎的药物，包括组合物A和组合物B，其中，所述组合物A包括2份医用蒸馏水、2份利多卡因注射液，所述组合物B包括左氧氟沙星注射液80份、医用葡萄糖粉8份，所述左氧氟沙星的浓度为0.2％。
在具体使用时，每天先利用组合物A做一次尿道灌注，以及利用组合物B进行第二次尿道灌注。如果没有灌进尿道，则再重新做，直到灌注进入到尿道中为止。
实施例二
一种用于治疗男性前列腺炎的药物，包括组合物A和组合物B，其中，所述组合物A包括8份医用蒸馏水、8份利多卡因注射液，所述组合物B包括左氧氟沙星注射液120份、医用葡萄糖粉12份，所述左氧氟沙星的浓度为0.2％。
其使用方法与实施例一相同。
实施例三
一种用于治疗男性前列腺炎的药物，包括组合物A和组合物B，其中，所述组合物A包括5份医用蒸馏水、5份利多卡因注射液，所述组合物B包括左氧氟沙星注射液100份、医用葡萄糖粉10份，所述左氧氟沙星的浓度为0.2％。
其使用方法与实施例一相同。
实施例四
在本实施例中，对上述实施例一至三的治疗效果进行验证。
针对前列腺炎综合症患者进行本发明提供的药物以及现有技术中的药物分别进行治疗，并在治疗期间保证患者不会服用其他影响准确性的药物，继而来验证本发明药物的药效。
将患者分为实验组、对比组以及空白组，每组10人，实验组服用本发明提供的药物，对比组服用现有技术中的药物，空白组不服用任何药物，进行为期三个月的观察记录实验。
结果可知：通过采用本发明提供的药物，不但能够达到治愈目的，降低复发率，其比现有技术中的药物具有更好的药效，而且对于多次治疗且耐药性强的患者依然适用。
因此，通过采用本发明提供的药物，能够达到治愈前列腺炎患者的作用，且复发率低，效果明显，从而大大降低了治疗成本，功能性强，解决了患者长期服药的抗药心理问题。
Claims (6)
- 一种用于治疗男性前列腺炎的药物，其特征在于，包括组合物A和组合物B，其中，所述组合物A包括2-8份医用蒸馏水、2-8份利多卡因注射液，所述组合物B包括左氧氟沙星注射液80-120份、医用葡萄糖粉8-12份，所述左氧氟沙星的浓度为0.2％。
- 根据权利要求1所述的一种用于治疗男性前列腺炎的药物，其特征在于，在使用过程中，在当日治疗中分别利用组合物A做一次尿道灌注，以及利用组合物B进行第二次尿道灌注。
- 根据权利要求1所述的一种用于治疗男性前列腺炎的药物，其特征在于，包括组合物A和组合物B，其中，所述组合物A包括2份医用蒸馏水、2份利多卡因注射液，所述组合物B包括左氧氟沙星注射液80份、医用葡萄糖粉8份，所述左氧氟沙星的浓度为0.2％。
- 根据权利要求1所述的一种用于治疗男性前列腺炎的药物，其特征在于，包括组合物A和组合物B，其中，所述组合物A包括8份医用蒸馏水、8份利多卡因注射液，所述组合物B包括左氧氟沙星注射液120份、医用葡萄糖粉12份，所述左氧氟沙星的浓度为0.2％。
- 根据权利要求1所述的一种用于治疗男性前列腺炎的药物，其特征在于，包括组合物A和组合物B，其中，所述组合物A包括5份医用蒸馏水、5份利多卡因注射液，所述组合物B包括左氧氟沙星注射液100份、医用葡萄糖粉10份，所述左氧氟沙星的浓度为0.2％。
- 一种如权利要求1-5任一项所述的药物的应用，其特征在于，所述药物用于治疗男性前列腺炎综合症。
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210595198.7A CN114931568A (zh) | 2022-05-28 | 2022-05-28 | 一种用于治疗男性前列腺炎的药物及其应用 |
| CN202210595198.7 | 2022-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2023231388A1 true WO2023231388A1 (zh) | 2023-12-07 |
Family
ID=82867504
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2022/141217 WO2023231388A1 (zh) | 2022-05-28 | 2022-12-23 | 一种用于治疗男性前列腺炎的药物及其应用 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN114931568A (zh) |
| WO (1) | WO2023231388A1 (zh) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114931568A (zh) * | 2022-05-28 | 2022-08-23 | 何明卫 | 一种用于治疗男性前列腺炎的药物及其应用 |
| CN115721607B (zh) * | 2022-11-19 | 2023-07-21 | 华夏生生药业(北京)有限公司 | 一种乳酸左氧氟沙星注射液及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709260A (zh) * | 2005-06-14 | 2005-12-21 | 舒尊鹏 | 前列腺萎缩抗炎注射液 |
| CN114931568A (zh) * | 2022-05-28 | 2022-08-23 | 何明卫 | 一种用于治疗男性前列腺炎的药物及其应用 |
-
2022
- 2022-05-28 CN CN202210595198.7A patent/CN114931568A/zh active Pending
- 2022-12-23 WO PCT/CN2022/141217 patent/WO2023231388A1/zh unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1709260A (zh) * | 2005-06-14 | 2005-12-21 | 舒尊鹏 | 前列腺萎缩抗炎注射液 |
| CN114931568A (zh) * | 2022-05-28 | 2022-08-23 | 何明卫 | 一种用于治疗男性前列腺炎的药物及其应用 |
Non-Patent Citations (3)
| Title |
|---|
| CHEN, JIJUN: "External Treatment of Chronic Prostatitis)", ZHONG GUO MIN JIAN LIAO FA = CHINA'S NATUROPATHY; CHINA FOLK TREATMENT, XX, CN, vol. 24, no. 09, 31 December 2016 (2016-12-31), CN , pages 77 - 78, XP009551070, ISSN: 1007-5798 * |
| JINXIANG ZHANG: "Observation on Curative Efficacy of Urethral Infusion with Drugs in Treatment of 96 Cases of Chronic Bacterial Prostatitis", MEDICINE AND PHARMACY OF YUNNAN, vol. 37, no. 1, 28 February 2016 (2016-02-28), pages 115 - 116, XP093116916 * |
| MINGWEI HE: "Analyzing Urethral Perfusion for the Treatment of Chronic Protatitis", HEBEI MEDICINE, vol. 18, no. 6, 30 June 2012 (2012-06-30), pages 751 - 754, XP093116915 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114931568A (zh) | 2022-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2023231388A1 (zh) | 一种用于治疗男性前列腺炎的药物及其应用 | |
| Zheng et al. | Effectiveness of abdominal acupuncture for patients with obesity-type polycystic ovary syndrome: a randomized controlled trial | |
| Madoff | Pharmacologic therapy for anal fissure | |
| Argov et al. | Radical, ambulatory hemorrhoidectomy under local anesthesia | |
| CN103263470B (zh) | 一种消肿止痛中药凝胶剂及其制备方法 | |
| CN103977194A (zh) | 能有效治疗创面感染的外用药在制备治疗糖尿病足药物中的应用 | |
| Chung et al. | Effects of acupuncture on abdominal leak point pressure and c-Fos expression in the brain of rats with stress urinary incontinence | |
| Huo et al. | Ultrasound‐Guided Capsular Thyroid Injection Therapy With Dexamethasone and Lidocaine Mixture for Subacute Thyroiditis: A Single‐Center Study | |
| Wang et al. | Pretreatment with transcutaneous electrical acupoint stimulation to prevent postoperative ileus in patients undergoing laparoscopic colon surgery: study protocol for a randomised controlled trial | |
| Chancellor et al. | Use of botulinum toxin in the genitourinary system | |
| Liu et al. | Efficacy of press needle treatment in reducing chemotherapy-induced nausea, vomiting, and retching gastrointestinal cancer patients: A randomized controlled trial | |
| Gelfman et al. | Prospective study of venous complications following intravenous diazepam in dental outpatients | |
| Lim et al. | Acupuncture treatment of dorsal wrist ganglion: Case report | |
| CN114099629B (zh) | 一种治疗乳腺结节经皮给药制剂及其制备方法 | |
| RU2810400C1 (ru) | Способ лечения стероидной розацеа по точкам | |
| Nema et al. | Efficacy of Ksharasootra In Arsho-Bhagandara (Piles and Fistula-In-Ano) In Single Sitting-A Case Study | |
| RU2687106C1 (ru) | Способ лечения синдрома гиперактивного мочевого пузыря | |
| Liang et al. | Analysis of vacuum negative pressure therapy and traditional Chinese medicine lavage in combination with tadalafil for vascular erectile dysfunction | |
| RU2552694C1 (ru) | Способ лечения больных хроническим бактериальным везикулитом | |
| Assi et al. | Efficacy of argentum-quartz solution in the treatment of perianal fistulas: A preliminary study | |
| Zhang et al. | Low molecular weight 35 kDa hyaluronan fragment HA35 in the treatment of bone metastasis pain: A case report | |
| Baker | The use of hyaluronidase in aesthetic medicine: a literature review | |
| CN1981865A (zh) | 一种疤痕治疗新的配方和使用方法 | |
| Yang et al. | Author Spotlight: Enhancing Women's Chronic Pelvic Pain Management Through Acupoint Catgut Embedding | |
| Gupta et al. | Genitourinary Issues in Spinal Cord Injury |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22944689 Country of ref document: EP Kind code of ref document: A1 |